Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

被引:9
|
作者
Haas, Jennifer S. [1 ]
Liang, Su-Ying [2 ]
Hassett, Michael J. [3 ]
Shiboski, Stephen [2 ]
Elkin, Elena B. [4 ]
Phillips, Kathryn A. [2 ]
机构
[1] Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02120 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
Breast cancer; Utilization; Genomics; RECURRENCE SCORE ASSAY; RT-PCR ASSAY; ECONOMIC-IMPLICATIONS; PROPENSITY SCORE; RISK; MULTICENTER; CLAIMS; IMPACT; WOMEN;
D O I
10.1007/s10549-011-1628-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As gene expression profile (GEP) testing for breast cancer may provide additional prognostic information to guide the use of adjuvant chemotherapy, we examined the association between GEP testing and use of chemotherapy, serious chemotherapy-related adverse effects, and total charges during the 12 months following diagnosis. Medical record review was conducted for women age 30-64 years, with incident, non-metastatic, invasive breast cancer diagnosed 2006-2008 in a large, national health plan. Of 534 patients, 25.8% received GEP testing, 68.2% received chemotherapy, and 10.5% experienced a serious chemotherapy-related adverse effect. GEP testing was most commonly used in women at moderate clinical risk of recurrence (52.0 vs. 25.0% of low-risk women and 5.5% of high-risk). Controlling for the propensity to receive GEP testing, women who had GEP were less likely to receive chemotherapy (propensity adjusted odds ratio, 95% confidence interval 0.62, 0.39-0.99). Use of GEP was associated with more chemotherapy use among women at low risk based on clinical characteristics (OR = 42.19; CI 2.50-711.82), but less use among women with a high risk based on clinical characteristics (OR = 0.12; CI 0.03-0.47). Use of GEP was not associated with chemotherapy for the moderate risk group. There was no significant relationship between GEP use and either serious chemotherapy-associated adverse effects or total charges. While GEP testing was associated with an overall decrease in adjuvant chemotherapy, we did not find differences in serious chemotherapy-associated adverse events or charges during the 12 months following diagnosis.
引用
收藏
页码:619 / 626
页数:8
相关论文
共 50 条
  • [21] The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations
    Laura Panattoni
    Tracy A. Lieu
    Jinani Jayasekera
    Suzanne O’Neill
    Jeanne S. Mandelblatt
    Ruth Etzioni
    Charles E. Phelps
    Scott D. Ramsey
    Breast Cancer Research and Treatment, 2019, 173 : 417 - 427
  • [22] The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations
    Panattoni, Laura
    Lieu, Tracy A.
    Jayasekera, Jinani
    O'Neill, Suzanne
    Mandelblatt, Jeanne S.
    Etzioni, Ruth
    Phelps, Charles E.
    Ramsey, Scott D.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 173 (02) : 417 - 427
  • [23] Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use
    Zanotti, Laura
    Bottini, Alberto
    Rossi, Camillo
    Generali, Daniele
    Cappelletti, Maria Rosa
    TUMOR BIOLOGY, 2014, 35 (09) : 8461 - 8470
  • [24] Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer
    Zhang, Xianglan
    Cha, In-Ho
    Kim, Ki-Yeol
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 116 - 128
  • [25] Patterns of 21-Gene Assay Testing and Chemotherapy Use in Black and White Breast Cancer Patients
    Sheppard, Vanessa B.
    O'Neill, Suzanne C.
    Dilawari, Asma
    Horton, Sara
    Hirpa, Fikru A.
    Isaacs, Claudine
    CLINICAL BREAST CANCER, 2015, 15 (02) : E83 - E92
  • [26] An update on chemotherapy and tumor gene expression profiles in breast cancer
    Tan, Sing-Huang
    Lee, Soo-Chin
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (09) : 1083 - 1113
  • [27] Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer
    Kolacinska, Agnieszka
    Fendler, Wojciech
    Szemraj, Janusz
    Szymanska, Bozena
    Borowska-Garganisz, Ewa
    Nowik, Magdalena
    Chalubinska, Justyna
    Kubiak, Robert
    Pawlowska, Zofia
    Blasinska-Morawiec, Maria
    Potemski, Piotr
    Jeziorski, Arkadiusz
    Morawiec, Zbigniew
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (07) : 7435 - 7441
  • [28] Gene Expression-Guided Adjuvant Chemotherapy in Breast Cancer
    Newman, Lisa A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (17): : 1681 - 1682
  • [29] Gene expression predicts chemotherapy response in advanced breast cancer
    Carol Lovegrove
    Nature Clinical Practice Oncology, 2005, 2 (12): : 602 - 602
  • [30] Gene expression profiling for individualized breast cancer chemotherapy: success or not?
    John PA Ioannidis
    Nature Clinical Practice Oncology, 2006, 3 : 538 - 539